Lupin will hold a meeting of the Board of Directors of the Company on 6 May 2024.Powered by Capital Market - Live News

Lupin has allotted 59,809 equity shares under ESOP on 18 April 2024. The issued and paid-up capital of the Company has been increased tot 91,15,00,208 consisting of 45,57,50, 104 equity shares of Rs 2/- each. Powered by Capital Market - Live News

Lupin announced that the United States Food and Drug Administration (U.S. FDA) has completed a GMP Inspection of its API manufacturing facility located at Dabhasa, India. The inspection was conducted from 08 April to 12 April 2024 and concluded with no observations. Powered by Capital Market - Live News

Lupin announced the appointment of Dr. Ranjana Pathak as Chief Quality Officer, succeeding Johnny Mikell who will be retiring from the services of the company.Dr. Pathak`s career includes serving as the Global Head for Quality and Pharmacovigilance at Dr. Reddy`s. Prior to this, Dr. Pathak served as the President & Global Head of Quality, Medical Affairs and Pharmacovigilance at Cipla and has also held Global Quality and Compliance leadership positions at Watson/Actavis and Endo Pharmaceuticals in the U.S. Dr. Pathak has strong experience across generic and brand medicines across dosage platforms including injectables, inhalation products and biologics. Powered by Capital Market - Live News

Lupin has allotted 52,041 equity shares under ESOP on 21 March 2024. With this allotment, the paid up equity share capital has increased to Rs 91,13,57,816 consisting of 45,56,78,908 equity shares of Rs 2 each. Powered by Capital Market - Live News